Stay updated on Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial
Sign up to get notified when there's something new on the Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial page.

Latest updates to the Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.2.0 was removed from the page.SummaryDifference0.1%

- Check25 days agoChange DetectedRemoved the government funding status notice about potential delays and NIH operations. This administrative change does not affect the study details, eligibility criteria, outcomes, or locations.SummaryDifference0.4%

- Check39 days agoChange DetectedThe screenshots display the same study details with no changes to the intervention, outcomes, or eligibility criteria; any differences seem to be cosmetic or layout adjustments.SummaryDifference0.5%

- Check68 days agoChange DetectedMajor update: new operating-status notice and a v3.2.0 version appears, replacing the old v3.1.0.SummaryDifference3%

- Check75 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

- Check89 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2. The 'Back to Top' UI element was removed; this is a minor change and the substantive update is the new release version.SummaryDifference0.2%

Stay in the know with updates to Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial page.